106 related articles for article (PubMed ID: 17885756)
1. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.
Liu G; Oettel K; Bailey H; Ummersen LV; Tutsch K; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Rezazadeh H; McGovern J; Robinson E; DeMets D; Wilding G
Invest New Drugs; 2003 Aug; 21(3):367-72. PubMed ID: 14578686
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Ripple GH; Gould MN; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Binger K; Tutsch KD; Pomplun M; Wahamaki A; Marnocha R; Wilding G; Bailey HH
Clin Cancer Res; 2000 Feb; 6(2):390-6. PubMed ID: 10690515
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
7. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
Stearns V; Coop A; Singh B; Gallagher A; Yamauchi H; Lieberman R; Pennanen M; Trock B; Hayes DF; Ellis MJ
Clin Cancer Res; 2004 Nov; 10(22):7583-91. PubMed ID: 15569989
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Azzoli CG; Miller VA; Ng KK; Krug LM; Spriggs DR; Tong WP; Riedel ER; Kris MG
Cancer Chemother Pharmacol; 2003 Jun; 51(6):493-8. PubMed ID: 12695855
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer.
Meadows SM; Mulkerin D; Berlin J; Bailey H; Kolesar J; Warren D; Thomas JP
Int J Gastrointest Cancer; 2002; 32(2-3):125-8. PubMed ID: 12794248
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of perillyl alcohol administered daily.
Ripple GH; Gould MN; Stewart JA; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Pomplun M; Wilding G; Bailey HH
Clin Cancer Res; 1998 May; 4(5):1159-64. PubMed ID: 9607573
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.
Bailey HH; Levy D; Harris LS; Schink JC; Foss F; Beatty P; Wadler S
Gynecol Oncol; 2002 Jun; 85(3):464-8. PubMed ID: 12051875
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
16. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.
DA Fonseca CO; Teixeira RM; Silva JC; DE Saldanha DA Gama Fischer J; Meirelles OC; Landeiro JA; Quirico-Santos T
Anticancer Res; 2013 Dec; 33(12):5625-31. PubMed ID: 24324108
[TBL] [Abstract][Full Text] [Related]
19. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol.
Ariazi EA; Satomi Y; Ellis MJ; Haag JD; Shi W; Sattler CA; Gould MN
Cancer Res; 1999 Apr; 59(8):1917-28. PubMed ID: 10213501
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer.
Paridaens R; Dirix L; Dumez H; Prové A; Wildiers H; Alvarez A; Oliveira CT; Latz J; Simms L; Melemed A
Clin Breast Cancer; 2007 Dec; 7(11):861-6. PubMed ID: 18269776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
